Genmab A/S (Nasdaq: GMAB) today announced that over 20 abstracts evaluating epcoritamab-bysp (EPKINLY®), a subcutaneously administered T-cell engaging bispecific antibody, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place December 7-10, 2024, at the San Diego Convention Center and online.
The extensive development program for epcoritamab will be showcased in four oral presentations at ASH 2024. Three of these will focus on the use of fixed-duration subcutaneous epcoritamab in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed/refractory (R/R) follicular lymphoma (FL). A fourth oral presentation will present data from a study on epcoritamab monotherapy in patients with R/R chronic lymphocytic leukemia (CLL). Additionally, the long-term efficacy and safety data from the EPCORE® NHL-1 trial in patients with R/R DLBCL will be presented.
“The data we are presenting at this year’s ASH meeting reflect the promising clinical results we’ve observed across epcoritamab trials,” said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. “We are excited to continue advancing the epcoritamab development program alongside our partner AbbVie, with the goal of offering new therapeutic options for patients with B-cell malignancies.”
The full list of accepted abstracts is now available on the ASH website.
2024 R&D Update and ASH Data Review
Genmab will host a virtual 2024 R&D Update and ASH Data Review on Wednesday, December 11, at 11:00 AM EST (5:00 PM CET / 4:00 PM GMT), where they will discuss data from the ASH presentations.
Key Abstracts for Presentation at ASH 2024
Oral Presentations
- 342 – Fixed-Duration Epcoritamab + R2 Induces Deep and Durable Responses in Relapsed/Refractory Follicular Lymphoma: 2-Year Follow-Up from the EPCORE NHL-2 Trial
Date/Time: Saturday, December 7, 4:00–5:30 PM PT - 581 – Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Untreated Diffuse Large B-Cell Lymphoma with High-Risk Features: Long-Term Results from the EPCORE NHL-2 Trial
Date/Time: Sunday, December 8, 12:00–1:30 PM PT - 867 – EPCORE DLBCL-3: First Disclosure of Epcoritamab Monotherapy in Older (≥75 years), Anthracycline-Ineligible Patients with Untreated Large B-Cell Lymphoma
Date/Time: Monday, December 9, 2:45–4:15 PM PT - 883 – Epcoritamab Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results from EPCORE CLL-1 Study
Date/Time: Monday, December 9, 2:45–4:15 PM PT
Poster Presentations
- 1414 – Exposure-Response Analyses Supporting Optimal Epcoritamab Dosing in Relapsed/Refractory Follicular Lymphoma
Date/Time: Saturday, December 7, 5:30–7:30 PM PT - 1622 – Epcoritamab with R-CHOP Overcomes Poor Risk Features of High Metabolic Tumor Volume in High-Risk Large B-Cell Lymphoma
Date/Time: Saturday, December 7, 5:30–7:30 PM PT - 1627 – Fixed-Duration Epcoritamab with Bendamustine + Rituximab for First-Line Follicular Lymphoma: Initial Results from EPCORE NHL-2 Arm 3
Date/Time: Saturday, December 7, 5:30–7:30 PM PT - 4480 – 3-Year Update from the EPCORE NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed/Refractory Large B-Cell Lymphoma
Date/Time: Monday, December 9, 6:00–8:00 PM PT
E-publications
- 7614 – Cost-Effectiveness of Epcoritamab vs Glofitamab in Relapsed/Refractory Large B-Cell Lymphoma
Publication Date: Available online
About Epcoritamab
Epcoritamab (EPKINLY®) is an investigational bispecific antibody created using Genmab’s DuoBody® technology. It binds to both CD3 on T-cells and CD20 on B-cells, leading to T-cell-mediated killing of CD20-positive B-cells. Epcoritamab has received regulatory approval in various lymphoma indications and is being co-developed by Genmab and AbbVie. The companies are collaborating to explore its use across multiple hematologic malignancies.
About Genmab
Genmab is a leading international biotechnology company focused on developing innovative antibody therapeutics. With a goal to transform the lives of patients by 2030, Genmab is dedicated to pioneering next-generation antibody treatments for cancer and other serious diseases.
